Back to Research

Organization profile

Anaveon AG

Anaveon AG is a clinical-stage immuno-oncology company that develops engineered cytokines to therapeutically enhance the immune system's response to tumors. The company's lead programs focus on selective Interleukin-2 (IL-2) agonists designed to expand tumor-fighting effector cells while avoiding the expansion of immunosuppressive regulatory T cells.

Basel, SwitzerlandFounded 2017

Overview

1. Executive Summary (Confidence: High)

Anaveon AG is a significant player in the longevity and immuno-oncology space, specializing in the engineering of interleukin-2 (IL-2) to overcome the historic toxicity and selectivity issues of first-generation treatments.[42] Founded as a spin-off from the University of Zurich and headquartered in Basel, the organization is backed by blue-chip investors including Syncona and the Novartis Venture Fund.[42] While its initial lead candidate, ANV419, successfully demonstrated safety and selective expansion of CD8+ and NK cells in Phase 1/2 trials, the company has strategically shifted its focus toward its next-generation "cis-signaling" molecule, ANV600.[43] ANV600 is designed to target IL-2 specifically to tumor-specific T cells by anchoring to PD-1, and is currently being evaluated in the "EXPAND-1" Phase 1/2 trial in combination with pembrolizumab (Keytruda) under a partnership with MSD.[45]

This is an extract of the full organization profile. To access the full company profile, .

Desktop only

Research is currently available on desktop only.

The Research module is designed for larger screens. Please reopen it on a desktop or laptop to use the screener, filters, detail pages, and admin tools.